Filtered By:
Source: Circulation
Condition: Heart Attack

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 272 results found since Jan 2013.

Applying Decision Analysis to Inform the US Food and Drug Administration's Benefit-Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS
Circulation. 2021 Aug 24;144(8):655-658. doi: 10.1161/CIRCULATIONAHA.120.053294. Epub 2021 Aug 23.NO ABSTRACTPMID:34424771 | DOI:10.1161/CIRCULATIONAHA.120.053294
Source: Circulation - August 23, 2021 Category: Cardiology Authors: Leila G Lackey Christine E Garnett Fred Senatore Source Type: research

Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial
Conclusions: The efficacy of rivaroxaban is associated with a benefit in surgical LER patients. While bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage or postprocedural bleeds requiring intervention. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02504216.PMID:34380322 | DOI:10.1161/CIRCULATIONAHA.121.054835
Source: Circulation - August 12, 2021 Category: Cardiology Authors: E Sebastian Debus Mark R Nehler Nicholas Govsyeyev Rupert M Bauersachs Sonia S Anand Manesh R Patel Fabrizio Fanelli Warren H Capell Taylor Brackin Franz Hinterreiter Dainis Krievins Patrice Nault Gabriele Piffaretti Alexei Svetlikov Nicole Jaeger Connie Source Type: research

Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Circulation. 2021 Jun 21:CIR0000000000000988. doi: 10.1161/CIR.0000000000000988. Online ahead of print.ABSTRACTObstructive sleep apnea (OSA) is characterized by recurrent complete and partial upper airway obstructive events, resulting in intermittent hypoxemia, autonomic fluctuation, and sleep fragmentation. Approximately 34% and 17% of middle-aged men and women, respectively, meet the diagnostic criteria for OSA. Sleep disturbances are common and underdiagnosed among middle-aged and older adults, and the prevalence varies by race/ethnicity, sex, and obesity status. OSA prevalence is as high as 40% to 80% in patients with ...
Source: Circulation - June 21, 2021 Category: Cardiology Authors: Yerem Yeghiazarians Hani Jneid Jeremy R Tietjens Susan Redline Devin L Brown Nabil El-Sherif Reena Mehra Biykem Bozkurt Chiadi Ericson Ndumele Virend K Somers American Heart Association Council on Clinical Cardiology; Council on Peripheral Vascular Diseas Source Type: research

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: Despite many differences in baseline characteristics between women and men and higher baseline endogenous factor Xa levels in women, the intensity of anticoagulation achieved with edoxaban between the sexes was similar. Treatment with higher-dose edoxaban regimen resulted in an even greater reduction in hemorrhagic stroke and several serious bleeding outcomes in women than in men, whereas the efficacy profile was similar between sexes. PMID: 33587659 [PubMed - as supplied by publisher]
Source: Circulation - February 16, 2021 Category: Cardiology Authors: Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA Tags: Circulation Source Type: research

Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.
khia MP, Van Gelder IC, Cooper LS, Al-Khatib SM Abstract Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected until complications such as stroke or heart failure occur. Hence, the public and clinicians have an intense interest in detecting AF earlier. However, the most appropriate strategies to detect undiagnosed AF (sometimes referred to as subclinical AF) and the prognostic and therapeutic implications of AF detect...
Source: Circulation - January 26, 2021 Category: Cardiology Authors: Benjamin EJ, Go AS, Desvigne-Nickens P, Anderson CD, Casadei B, Chen LY, Crijns HJGM, Freedman B, Hills MT, Healey JS, Kamel H, Kim DY, Link MS, Lopes RD, Lubitz SA, McManus DD, Noseworthy PA, Perez MV, Piccini JP, Schnabel RB, Singer DE, Tieleman RG, Tur Tags: Circulation Source Type: research

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial.
Conclusions: The safety and efficacy of apixaban was consistent irrespective of kidney function, as compared with warfarin, and in accordance with the overall trial results. The risk of bleeding with aspirin was consistently higher across all kidney function categories. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02415400. PMID: 33461308 [PubMed - as supplied by publisher]
Source: Circulation - January 19, 2021 Category: Cardiology Authors: Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, Parkhomenko A, Bahit MC, Windecker S, Aronson R, Berwanger O, Halvorsen S, de Waha-Thiele S, Sinnaeve P, Darius H, Storey RF, Lopes RD Tags: Circulation Source Type: research

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL did not appear to derive further reduction in the risk of MACE compared to those who achieved LDL-C levels of 25-50 mg/dL. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402. PMID: 33438437 [PubMed - as supplied by publisher]
Source: Circulation - January 13, 2021 Category: Cardiology Authors: Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research

Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
Conclusions: Risk of residual confounding cannot be fully excluded. Individual therapeutic agents within each class may have different magnitudes of effect. In this large real-world cohort of diabetic patients already on GLP-1RA, addition of SGLT2i - compared to addition of sulfonylurea - conferred greater cardiovascular benefit. The magnitude of the cardiovascular risk reduction was comparable to the benefit seen in cardiovascular outcome trials of SGLT2i versus placebo where baseline GLP-1RA use was minimal. PMID: 33302723 [PubMed - as supplied by publisher]
Source: Circulation - December 11, 2020 Category: Cardiology Authors: Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E Tags: Circulation Source Type: research

Temporal Changes in Secondary Prevention and Cardiovascular Outcomes after Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study.
Conclusions: Medical prevention of adverse events has increased considerably over time in patients that underwent revascularization for symptomatic PAD. This increase was accompanied by reductions in all adverse outcomes, except major amputations. PMID: 33300375 [PubMed - as supplied by publisher]
Source: Circulation - December 10, 2020 Category: Cardiology Authors: Søgaard M, Nielsen PB, Skjøth F, Eldrup N, Larsen TB Tags: Circulation Source Type: research

Number of Social Determinants of Health and Fatal and Nonfatal Incident Coronary Heart Disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
Conclusions: A greater burden of SDH was associated with a graded increase in risk of incident CHD, with greater magnitude and independent associations for fatal incident CHD. Counting the number of SDH may be a promising approach that could be incorporated into clinical care to identify individuals at high risk of CHD. PMID: 33269599 [PubMed - as supplied by publisher]
Source: Circulation - December 3, 2020 Category: Cardiology Authors: Safford MM, Reshetnyak E, Sterling MR, Richman JS, Muntner PM, Durant RW, Booth J, Pinheiro LC Tags: Circulation Source Type: research

Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry.
Conclusions: Although in-hospital mortality and MACE did not differ by race/ethnicity after adjustment, Black and Hispanic patients bore a greater burden of mortality and morbidity due to their disproportionate representation among COVID-19 hospitalizations. PMID: 33200953 [PubMed - as supplied by publisher]
Source: Circulation - November 17, 2020 Category: Cardiology Authors: Rodriguez F, Solomon N, de Lemos JA, Das SR, Morrow DA, Bradley SM, Elkind MSV, Williams Iv JH, Holmes D, Matsouaka RA, Gupta D, Gluckman TJ, Abdalla M, Albert MA, Yancy CW, Wang TY Tags: Circulation Source Type: research